Core Points - Hongyuan Pharmaceutical (301246.SZ) reported a revenue of 883 million yuan for the first half of 2025, a year-on-year decrease of 1.73% [1] - The net profit attributable to shareholders was -5.81 million yuan, compared to a profit of 35.81 million yuan in the same period last year [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was -21.59 million yuan, down from 14.68 million yuan year-on-year [1] - The net cash flow from operating activities was -170 million yuan, compared to -18.46 million yuan in the previous year [1] Fundraising and IPO Details - Hongyuan Pharmaceutical raised a total of 2.36 billion yuan from its initial public offering, with a net amount of 2.20 billion yuan after deducting issuance costs [2] - The final net fundraising amount exceeded the original plan by 1.55 billion yuan [2] - The company initially planned to raise 650 million yuan for projects including a research center and a high-end formulation workshop with an annual production capacity of 2.5 billion pieces [2] - The total issuance costs amounted to 167 million yuan, with underwriting fees accounting for 139.32 million yuan [2]